ATNM Form 4: Sandesh Seth RSU Vesting, 120,900 Shares Withheld
Rhea-AI Filing Summary
Actinium Pharmaceuticals insider filing: Sandesh Seth, the company's Chief Executive Officer and a Director, reported a transaction dated 08/18/2025 relating to his common stock holdings in Actinium Pharmaceuticals (ATNM). The Form 4 discloses that 120,900 shares were withheld at a price of $1.71 to satisfy tax withholding obligations arising from the vesting of 300,000 restricted stock units (RSUs) that were granted to Mr. Seth on 08/17/2022. After the withholding, Mr. Seth beneficially owned 184,481 shares. The filing explains the RSUs were granted in exchange for previously issued warrants that had vested earlier and whose expiration dates and exercise were adjusted by the board to align his interests with stockholders.
Positive
- Board alignment action: The company converted prior warrants into 300,000 RSUs to align executive and stockholder interests.
- Transparent disclosure: The Form 4 clearly explains the withholding of 120,900 shares to meet tax obligations related to RSU vesting.
Negative
- None.
Insights
TL;DR: Routine insider tax-withholding on RSU vesting; modest change in beneficial ownership, no new cash purchase or sale.
The Form 4 documents a non-cash transaction where 120,900 shares were withheld to cover taxes on the vesting of 300,000 RSUs granted in 2022. This is an administrative, not a market, transaction and does not represent a discretionary open-market sale by the CEO. The remaining beneficial ownership of 184,481 common shares is disclosed; the reported withholding price of $1.71 provides a reference for the tax calculation but is not a market trade price. From a financial perspective, this is neutral for valuation models because it reflects compensation settlement rather than cash proceeds to the executive or a signal of directional selling.
TL;DR: Board-mediated award conversion to RSUs and withholding are governance actions to align management with shareholders.
The filing explains a governance arrangement where warrants issued for prior services were effectively converted into RSUs in 2022 to maintain alignment between Mr. Seth and shareholders. The board extended and later refrained from requiring exercise of warrants, substituting RSUs based on average prior fair value. The current withholding to satisfy tax obligations on RSU vesting is a routine administrative outcome of that governance decision. This disclosure is a transparent record of insider compensation mechanics and does not indicate unusual governance risk or contested action.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 120,900 | $1.71 | $207K |
Footnotes (1)
- F1. Represents shares of common stock withheld to pay Mr. Seth's tax withholding obligations incurred in connection with the vesting of 300,000 restricted stock units, or RSUs, on August 18, 2025. On August 17, 2022, Mr. Seth was granted an award of 300,000 RSUs, in exchange for warrants granted to Mr. Seth on December 17, 2012 for services provided to the Company prior to becoming employed by Actinium. The warrants were in the money since vesting on December 17, 2013. Mr. Seth refrained from exercising the warrants to be aligned with the long-term interests of the Company and stockholders. In November 2018, the Board extended the expiration of Mr. Seth's warrants to February 2022. In February 2022, the Company requested that Mr. Seth not exercise the warrants. In exchange, the Board determined to grant Mr. Seth 300,000 RSUs based on the average fair value of the warrants during their vested life to continue to align Mr. Seth with the long-term interest of the Company and stockholders.
AI-generated analysis. How Rhea-AI works. Not financial advice.
